NEW YORK, NY, Nov. 7, 2013 /PRNewswire/ - Anavex Life Sciences Corp. (OTCQB:
AVXL) is pleased to announce that its President and Chief Executive
Officer Christopher U. Missling, PhD, will be presenting new clinical
predication data supporting its investigational compound, ANAVEX 2-73,
as a potential therapeutic for the treatment of Alzheimer's disease.
The data will be unveiled in a poster presentation at the CNS Summit 2013, which takes place November 14-17, 2013 in Boca Raton, Florida. The
poster presentation was co-authored by Tangui Maurice, PhD, INSERM;
Athan Spiros, In Silico BioSciences (ISB); Patrick Roberts, ISB and
Oregon Health & Science University; and, Hugo Geerts, ISB and
University of Pennsylvania.

The findings will be presented during the following poster session:

Title:

The anticipated clinical effect of the new Alzheimer drug ANAVEX 2-73 in
a calibrated Quantitative Systems Pharmacology Platform

Date:

Saturday, November 16, 2013

Time:

5:00 PM - 7:00 PM ET

Place:

The Boca Raton Waldorf Astoria

501 East Camino Real, Boca Raton, FL 33432

ANAVEX 2-73 is an orally available small molecule being investigated for
the treatment of Alzheimer's disease. In addition to pre-clinical data
indicating that ANAVEX 2-73 has the potential to prevent, halt and/or
reverse the course of Alzheimer's disease, there was also a highly
encouraging synergistic effect observed between ANAVEX 2-73 and
Aricept® (donepezil). The combined therapeutics produced up to 80%
greater reversal of memory loss in Alzheimer's disease models versus
when the drugs were used individually.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (www.anavex.com) is a clinical stage biopharmaceutical company engaged in the
development of novel drug candidates to treat Alzheimer's, CNS diseases
and various types of cancer. ANAVEX 2-73, a drug candidate developed
to treat Alzheimer's through potential disease modification, has
undergone an initial Phase 1 human clinical trial and was well
tolerated in doses up to 55mg. Results from pre-clinical studies
indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective
properties. Anavex is a publicly traded corporation quoted as AVXL.

Forward-Looking Statements

Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks set forth in the Company's most
recent Annual Report on Form 10-K filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof.

Anavex Life Sciences Corp. Research & Business Development Email: info@anavex.com